AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15242436 — intervention group
Group type: COMPARATOR
Intervention: 65% nitrogen in air (control)
Number of subjects: 344
Study 11694805 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol (50 microg)
Number of subjects: 26
Study 11694805 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zafirlukast (40 mg)
Number of subjects: 26
Study 11694805 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of inhaled salmeterol and oral zafirlukast
Number of subjects: 26
Study 11694805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 9394056 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR) training
Number of subjects: 60
Study 9394056 — intervention group
Group type: COMPARATOR
Intervention: Contact with the investigator (Control)
Number of subjects: 60
Study 8194818 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSO gel 10% applied three times a day (n = 77)
Number of subjects: 157
Study 8194818 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel excipient (n = 80)
Number of subjects: 157
Study 3311442 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast self-examination (BSE)
Number of subjects: 62000
Study 3311442 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 62000
Study 31858950 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-delivered inferencing training
Number of subjects: 100
Study 31858950 — intervention group
Group type: COMPARATOR
Intervention: Active control condition of daily maths activities
Number of subjects: 100
Study 29505806 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent community intervention (community mobilisation, social marketing, monitoring of alcohol sales to minors)
Number of subjects: 3545
Study 29505806 — intervention group
Group type: COMPARATOR
Intervention: Control communities
Number of subjects: 3545
Study 27400966 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondirective coaching
Number of subjects: 518
Study 27400966 — intervention group
Group type: COMPARATOR
Intervention: Directive coaching
Number of subjects: 518
Study 27400966 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondirective coaching for subgroups (income above median, recent quit attempts, alternative therapies)
Number of subjects: 518
Study 27400966 — intervention group
Group type: EXPERIMENTAL
Intervention: Waiting up to 4 weeks to start coaching
Number of subjects: 518
Study 27400966 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly addicted or depressed smokers who had never quit more than 30 days
Number of subjects: 518
Study 24522623 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery incentive with expected daily value of $1.40 (n=21)
Number of subjects: 75
Study 24522623 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery incentive with expected daily value of $2.80 (n=26)
Number of subjects: 75
Study 24522623 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=28)
Number of subjects: 75
Study 22024898 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative rehabilitation program (12 classes starting 6 weeks after surgery)
Number of subjects: 105
Study 22024898 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 105
Study 22024898 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational booklet provided at hospital discharge (part of the intervention)
Number of subjects: 105
Study 20068289 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinegar (10 g) during mealtime
Number of subjects: 10
Study 20068289 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinegar (10 g) 5 hours before meal
Number of subjects: 10
Study 20068289 — intervention group
Group type: COMPARATOR
Intervention: Sodium acetate (neutralized salt)
Number of subjects: 10
Study 20068289 — intervention group
Group type: COMPARATOR
Intervention: Vinegar with monosaccharides
Number of subjects: 10
Study 19008149 — intervention group
Group type: COMPARATOR
Intervention: BNP guided therapy
Number of subjects: 0
Study 19008149 — intervention group
Group type: COMPARATOR
Intervention: MR-proANP
Number of subjects: 0
Study 19008149 — intervention group
Group type: COMPARATOR
Intervention: Ivabradine
Number of subjects: 0
Study 19008149 — intervention group
Group type: COMPARATOR
Intervention: n-3 PUFA
Number of subjects: 0
Study 19008149 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin
Number of subjects: 0
Study 19008149 — intervention group
Group type: COMPARATOR
Intervention: Telemonitoring support
Number of subjects: 0
Study 16079784 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimates of k(loss) and EDV(2) using a novel application of a multilinear solution for the two-tissue compartment FDOPA model.
Number of subjects: 0
Study 16079784 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilinear estimates of EDV(2)
Number of subjects: 0
Study 16079784 — intervention group
Group type: EXPERIMENTAL
Intervention: k(loss)
Number of subjects: 0
Study 12495948 — intervention group
Group type: EXPERIMENTAL
Intervention: Site specific advice from a school travel coordinator
Number of subjects: 21
Study 12495948 — intervention group
Group type: COMPARATOR
Intervention: Control group (no site specific advice)
Number of subjects: 21
Study 10423659 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (n = 385)
Number of subjects: 578
Study 10423659 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril (n = 193)
Number of subjects: 578
Study 10423659 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 578
Study 10423659 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 578
Study 8888660 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 45
Study 8888660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 1848131 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorothiazide
Number of subjects: 42
Study 1848131 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 42
Study 1848131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 6844367 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentermine (30 mg capsule daily)
Number of subjects: 99
Study 6844367 — intervention group
Group type: COMPARATOR
Intervention: Diethylpropion (75 mg tablet daily)
Number of subjects: 99
Study 6844367 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentermine
Number of subjects: 99
Study 6844367 — intervention group
Group type: COMPARATOR
Intervention: Diethylpropion
Number of subjects: 99
Study 30335676 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom training program for promoting health literacy
Number of subjects: 171
Study 27659772 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding counselling sessions
Number of subjects: 3188
Study 27659772 — intervention group
Group type: COMPARATOR
Intervention: Usual health messages (Control)
Number of subjects: 3188
Study 27659772 — intervention group
Group type: COMPARATOR
Intervention: Multiple micronutrients (Control)
Number of subjects: 3188
Study 25895909 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with standardized JC pollen extract (CEDARTOLEN®) at a maintenance dose of 2,000 Japanese allergy units (JAU)
Number of subjects: 531
Study 25895909 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with standardized JC pollen extract (CEDARTOLEN®)
Number of subjects: 531
Study 25895909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 531
Study 23900032 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinguistic cognitive processing treatment
Number of subjects: 59
Study 23900032 — intervention group
Group type: EXPERIMENTAL
Intervention: English treatment
Number of subjects: 59
Study 23900032 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilingual (Spanish-English) treatment
Number of subjects: 59
Study 23900032 — intervention group
Group type: COMPARATOR
Intervention: Deferred treatment
Number of subjects: 59
Study 21114792 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole-ER 50 mg
Number of subjects: 2130
Study 20020622 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 level in peritoneal exudate
Number of subjects: 189
Study 20020622 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak value of interleukin-6
Number of subjects: 189
Study 17298254 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone
Number of subjects: 177
Study 17298254 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine
Number of subjects: 177
Study 17298254 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 177
Study 12612143 — intervention group
Group type: COMPARATOR
Intervention: SPE chips and spread group (17 g/d SPE)
Number of subjects: 380
Study 12612143 — intervention group
Group type: COMPARATOR
Intervention: SPE spread (10 g/d SPE)
Number of subjects: 380
Study 12612143 — intervention group
Group type: COMPARATOR
Intervention: SPE chips (7 g/d SPE)
Number of subjects: 380
Study 12612143 — intervention group
Group type: COMPARATOR
Intervention: All SPE groups
Number of subjects: 380
Study 12612143 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 380
Study 10690834 — intervention group
Group type: EXPERIMENTAL
Intervention: Near confluent laser treatment
Number of subjects: 58
Study 10690834 — intervention group
Group type: COMPARATOR
Intervention: Less dense treatment
Number of subjects: 58
Study 9062865 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (1 mg)
Number of subjects: 12
Study 9062865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8400484 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal hearing group (10 subjects)
Number of subjects: 30
Study 8400484 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately hearing-impaired group (10 subjects)
Number of subjects: 30
Study 8400484 — intervention group
Group type: EXPERIMENTAL
Intervention: Profoundly hearing-impaired group (10 subjects)
Number of subjects: 30
Study 3720569 — intervention group
Group type: EXPERIMENTAL
Intervention: Special intervention (cholesterol lowering dietary advice, behaviour modification for cigarette smoking, stepped care pharmacological approach)
Number of subjects: 0
Study 3720569 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 3720569 — intervention group
Group type: EXPERIMENTAL
Intervention: Special intervention (diuretic use)
Number of subjects: 0
Study 3720569 — intervention group
Group type: EXPERIMENTAL
Intervention: Special intervention (hydrochlorothiazide)
Number of subjects: 0
Study 30340813 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry functional beverage (CFB), 750 ml daily for 8 weeks
Number of subjects: 50
Study 30340813 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 50
Study 30340813 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry functional beverage (CFB)
Number of subjects: 50
Study 27362613 — intervention group
Group type: EXPERIMENTAL
Intervention: Lens wear with recovery periods of 0, 30, 60, or 80 minutes
Number of subjects: 25
Study 27362613 — intervention group
Group type: COMPARATOR
Intervention: Spectacle (no lens)
Number of subjects: 25
Study 25541817 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 103
Study 25541817 — intervention group
Group type: COMPARATOR
Intervention: Regional anesthesia
Number of subjects: 103
Study 22453675 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietex™ ProGrip™ mesh (P group)
Number of subjects: 302
Study 22453675 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein repair with lightweight polypropylene mesh (L group)
Number of subjects: 302
Study 22453675 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietex™ ProGrip™ mesh without fixation
Number of subjects: 302
Study 20400496 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals with 250 to 3000 kcal containing 500 mg of calcium
Number of subjects: 6
Study 20400496 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals with lower protein and higher fat content
Number of subjects: 6
Study 18339798 — intervention group
Group type: EXPERIMENTAL
Intervention: All-extremity semirecumbent exercise machine
Number of subjects: 18
Study 18339798 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable metabolic unit
Number of subjects: 18
Study 15606569 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum needles
Number of subjects: 28
Study 15606569 — intervention group
Group type: COMPARATOR
Intervention: Placebo needles
Number of subjects: 28
Study 12679604 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity standard exercise modalities, 24 sessions (45 min each) over 8-10 weeks
Number of subjects: 245
Study 12679604 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 245
Study 12679604 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity standard exercise modalities
Number of subjects: 245
Study 11041534 — intervention group
Group type: COMPARATOR
Intervention: Clozapine
Number of subjects: 19
Study 11041534 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 19
Study 8674787 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin (ROM) administered for 8 weeks
Number of subjects: 30
Study 1839759 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin 15 mg/kg
Number of subjects: 15
Study 1839759 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin 20 mg/kg
Number of subjects: 15
Study 1839759 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin 25 mg/kg
Number of subjects: 15
Study 1839759 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl placebo
Number of subjects: 15
Study 6636790 — intervention group
Group type: EXPERIMENTAL
Intervention: Inderal 40 mg
Number of subjects: 26
Study 6636790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 6636790 — intervention group
Group type: EXPERIMENTAL
Intervention: Inderal 40 mg (in soldiers with anxiety and high pulse)
Number of subjects: 26
Study 31447129 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fixed-dose combination (FDC) of ibuprofen 300 mg + acetaminophen 1000 mg
Number of subjects: 276
Study 31447129 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 300 mg
Number of subjects: 276
Study 31447129 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen 1000 mg
Number of subjects: 276
Study 31447129 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 276
Study 30126463 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile fresh fruit and vegetable (F&V) markets plus nutrition education (e.g. campaigns, DVDs, newsletters, recipes, and chef demonstrations)
Number of subjects: 1597
Study 30126463 — intervention group
Group type: COMPARATOR
Intervention: Physical activity and stress interventions
Number of subjects: 1597
Study 26575696 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with Dermatophagoides farinae (Der.f) drops
Number of subjects: 500
Study 26575696 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with Dermatophagoides farinae (Der.f) drops (SLIT3 subgroup)
Number of subjects: 500
Study 26575696 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with Dermatophagoides farinae (Der.f) drops (SLIT1 and SLIT2 subgroups)
Number of subjects: 500
Study 26575696 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy with oral antihistamines
Number of subjects: 500
Study 25155941 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance‐Enhanced Behavior Therapy for Trichotillomania
Number of subjects: 90
Study 25155941 — intervention group
Group type: EXPERIMENTAL
Intervention: AAQ‐TTM
Number of subjects: 90
Study 21641726 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU intranasally)
Number of subjects: 38
Study 21641726 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 38
Study 20963638 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (ifosfamide, DTIC, and doxorubicin administered in 14-day intervals supported by G-CSF on days 5-13)
Number of subjects: 59
Study 20963638 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (control group)
Number of subjects: 59
Study 20963638 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (ifosfamide, DTIC, and doxorubicin)
Number of subjects: 59
Study 17351950 — intervention group
Group type: COMPARATOR
Intervention: Oral gefitinib 250 mg daily (G arm)
Number of subjects: 48
Study 17351950 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine 15 mg/m2 as an intravenous infusion on Day 1 and oral gefitinib 250 mg daily on Days 2 through 14 every 2 weeks (GV arm)
Number of subjects: 48
Study 16278618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study 16278618 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2) 0.25 mg
Number of subjects: 327
Study 16278618 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2) 0.5 mg
Number of subjects: 327
Study 16278618 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2) 1 mg
Number of subjects: 327
Study 16278618 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2) 1 mg/NETA 0.25 mg
Number of subjects: 327
Study 16278618 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2) 1 mg/NETA 0.5 mg
Number of subjects: 327
Study 16278618 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2) 2 mg/NETA 1 mg
Number of subjects: 327
Study 16278618 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (all E(2) groups)
Number of subjects: 327
Study 11932567 — intervention group
Group type: EXPERIMENTAL
Intervention: Acustat electro‐membrane microcurrent therapy
Number of subjects: 30
Study 11932567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9806695 — intervention group
Group type: COMPARATOR
Intervention: sham-TENS (no electrical current) at the Zusanli (ST36) acupoints
Number of subjects: 100
Study 9806695 — intervention group
Group type: EXPERIMENTAL
Intervention: nonacupoint-TENS at the shoulders
Number of subjects: 100
Study 9806695 — intervention group
Group type: EXPERIMENTAL
Intervention: dermatomal-TENS at the level of the surgical incision
Number of subjects: 100
Study 9806695 — intervention group
Group type: EXPERIMENTAL
Intervention: acupoint-TENS at the Zusanli acupoints
Number of subjects: 100
Study 7620745 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning light treatment (8.00-8.30 a.m., n = 14)
Number of subjects: 68
Study 7620745 — intervention group
Group type: EXPERIMENTAL
Intervention: Afternoon light treatment (1.00-1.30 p.m., n = 15)
Number of subjects: 68
Study 7620745 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening light treatment (8.00-8.30 p.m., n = 12)
Number of subjects: 68
Study 7620745 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning light treatment followed by evening light (n = 13)
Number of subjects: 68
Study 7620745 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening light treatment followed by morning light (n = 14)
Number of subjects: 68
Study 2371420 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic obstructive airways disease subjects using an alcolmeter simulator
Number of subjects: 36
Study 2371420 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects using the roadside alcolmeter at flow rates of 10 l min‐1 and 40 l min‐1
Number of subjects: 36
Study 2371420 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with chronic obstructive airways disease who are drivers or ex-drivers
Number of subjects: 36
Study 7318359 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg by mouth)
Number of subjects: 6
Study 31978983 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Addiction Model (FAM) explanation for weight control and obesity
Number of subjects: 1220
Study 31978983 — intervention group
Group type: COMPARATOR
Intervention: Diet and exercise explanation
Number of subjects: 1220
Study 31978983 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1220
Study 30385320 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate- to high-interfering persistent pain group
Number of subjects: 145
Study 30385320 — intervention group
Group type: EXPERIMENTAL
Intervention: Low perceptual load conditions
Number of subjects: 145
Study 30385320 — intervention group
Group type: COMPARATOR
Intervention: Non-chronic pain and low-interfering persistent pain groups
Number of subjects: 145
Study 29219095 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance with any individual guideline
Number of subjects: 202
Study 29219095 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance with any combination of two guidelines
Number of subjects: 202
Study 29219095 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance with all three guidelines
Number of subjects: 202
Study 29219095 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall compliance with the 24 h movement guidelines
Number of subjects: 202
Study 29219095 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity guideline compliance
Number of subjects: 202
Study 29219095 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep guideline compliance
Number of subjects: 202
Study 29219095 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior guideline compliance
Number of subjects: 202
Study 25595104 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinized solution (lidocaine 1% and epinephrine in sodium bicarbonate 1.4%)
Number of subjects: 101
Study 25595104 — intervention group
Group type: COMPARATOR
Intervention: Standard solution (lidocaine 1% and epinephrine in saline 0.9%)
Number of subjects: 101
Study 24468092 — intervention group
Group type: EXPERIMENTAL
Intervention: high-frequency repetitive TMS (hf rTMS) (10 Hz) on left DLPFC
Number of subjects: 14
Study 24468092 — intervention group
Group type: COMPARATOR
Intervention: sham stimulation (vertex)
Number of subjects: 14
Study 22748702 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 10 mg twice daily
Number of subjects: 352
Study 22748702 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 20 mg twice daily
Number of subjects: 352
Study 22748702 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice daily
Number of subjects: 352
Study 22748702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352